The Thousand Oaks, California-based company also is developing an oral medicine and other treatments for obesity, but has disclosed few details about them
What is Dimensional Weight
Results from a post hoc subgroup analysis of the SURMOUNT-1 study (NCT04184622), published this year [87] , demonstrated that among 32 pathogenic MC4R variant carriers (1.4% of the study population) with a median age of 41.06 years and a BMI 40 kg/m 2 , treatment with tirzepatide for 72 weeks resulted in an 18.3% reduction in body weight from baseline
Summary: GLP-1 medications may not work due to insufficient dosing, individual biological variation in receptor function, advanced beta cell dysfunction, lifestyle factors, or unrealistic expectations about treatment timelines and outcomes
In- stock items ordered after 11am, will be dispatched next business day